Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyCareOregon weekly GLP-1 Prior Auth Policy Update |…
    Ask Trek AI about this page
    CurrentcareoregonPolicy N/A

    Diabetic GLP-1 Agonists (Weekly) — Prior Authorization Guideline

    Customize your policy alerts

    Sign up for all careoregon policy alerts

    Know when careoregon releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization requirements for weekly GLP-1 receptor agonists for treatment of diabetes (products listed include Exenatide, Mounjaro, Trulicity, Ozempic) affecting CareOregon members on the referenced formulary.

    Policy Summary
    Payercareoregon
    PolicyDiabetic GLP-1 Agonists (Weekly) — Prior Authorization Guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 21, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documenting required trials (including liraglutide) and a recent HbA1c within 6 months for reauthorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsstandard approval length
    HbA1c ≤6 morequired lab for reauthorization
    BMI >30weight threshold
    4+named products

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Weekly GLP-1 Agonists

    Initial Authorization

    Covered when ALL of the following are met

    Primary requirements

    • Pathway

      • 2.1: ASCVD or CKD pathway: Both of the following: (1) Patient has ASCVD OR chronic kidney disease with eGFR 25-75 mL/min/1.73 m2 and UACR greater than 100 mg/g; AND (2) one of: trial and failure/contraindication/intolerance to an SGLT2 inhibitor OR both continued treatment with an SGLT2 inhibitor and HbA1c > 7%
      • 2.2: Multiple oral therapy failure pathway: All of the following: trial and failure or contraindication to metformin; HbA1c > 7%; and a minimum 3-month trial and failure to TWO of: sulfonylurea (e.g., glipizide, glimepiride), pioglitazone, alogliptin, or an SGLT2 inhibitor (at maximum tolerated doses)

        Prior authorization is required for some agents

    Liraglutide and coadministration restrictions

    Liraglutide and coadministration: Trial and failure or contraindication to liraglutide is required; medication must not be co-administered with another GLP-1 receptor agonist or GIP (e.g., Mounjaro).

    Reauthorization

    Covered when ALL of the following are met for reauthorization

    Reauthorization core: At least one HbA1c has been obtained in the previous 6 months (If HbA1c is not provided, only approve for 2 months one time; deny after first grace authorization for lack of A1c).
    Diabetes continuation pathway: Either ongoing therapy with metformin (trial of and will continue therapy with metformin) OR documented failure/contraindication/intolerance to metformin.

    Obstructive Sleep Apnea (OSA) indication / Reauthorization

    Covered when ALL of the following are met

    OSA-related criteria: Diagnosis of moderate to severe obstructive sleep apnea confirmed by polysomnography; BMI > 30 kg/m2; patient has fully maximized positive airway pressure (PAP) therapy OR submission of medical records documenting inability to tolerate PAP; trial and failure or contraindication to liraglutide; and patient has tried a weight loss treatment plan administered by a health care provider for at least a 3-month period within the past 6 months.
    Continuing OSA criteria: Submission of medical records documenting a reduction in sleep-related impairment AND patient is continuing treatment with positive airway pressure therapy OR at least one HbA1c has been obtained in the previous 6 months (If HbA1c not provided, see reauthorization grace policy).

    The requested medication must not be co‑administered with another GLP‑1 receptor agonist or a dual GIP/GLP‑1 agent (for example, Mounjaro). Additionally, a documented trial and failure or a contraindication to liraglutide is required before approval of the weekly GLP‑1 agent.

    For reauthorization and certain continuation pathways, the policy requires at least one HbA1c obtained within the previous 6 months. If an HbA1c value is not provided, the plan will grant a one‑time 2‑month grace approval; subsequent requests lacking a recent HbA1c will be denied for failure to meet reauthorization requirements.

    Clinical Parameters and Coding-related Criteria

    inv-07: eGFR and UACR — eGFR 25-75 mL/min/1.73 m2 and UACR > 100 mg/g
    eGFR range25-75 mL/min/1.73 m2
    UACR threshold> 100 mg/g
    ContextSpecified as part of chronic kidney disease criteria for pathway to approval
    inv-08: Body mass index (BMI) — BMI > 30 kg/m2
    BMI threshold> 30 kg/m2
    Indication contextRequired for obstructive sleep apnea (OSA)–related weight-loss pathway
    Source evidenceDocument lists BMI > 30 kg/m2 as a criterion for OSA indication
    inv-09: Hemoglobin A1c (HbA1c) — HbA1c > 7% or at least one HbA1c obtained in prior 6 months
    Primary HbA1c threshold> 7% where specified
    Reauthorization monitoringAt least one HbA1c obtained in the previous 6 months
    Grace policyIf HbA1c is not provided, only a one-time 2-month approval may be granted; subsequent requests denied for lack of A1c

    Provider Actions, Documentation & Prior Authorization

    Prior Authorization

    Prior authorization required — weekly GLP‑1 agonists

    Prior authorization is required for the listed weekly GLP‑1 receptor agonists. Standard approval length is 12 months.

    Step Therapy

    Step therapy: required trials/failures or contraindications

    Document trials and either failures or contraindications to required prior therapies before approval: metformin, specified oral agents, SGLT2 inhibitors, and liraglutide. For the multiple‑oral‑therapy pathway, two distinct 3‑month trials at maximum tolerated doses are required.

    • Trial and failure or contraindication to metformin (required pathway option).
    • For the multi‑oral pathway: trial and failure (minimum 3 months each) to TWO of: sulfonylurea (e.g., glipizide, glimepiride), pioglitazone, alogliptin, or an SGLT2 inhibitor.
    • Trial and failure or contraindication to liraglutide is required (separate requirement).
    • If using the ASCVD/CKD pathway: trial and failure/contraindication to an SGLT2 inhibitor OR continued SGLT2 therapy with HbA1c >7%.
    Documentation Required

    Supporting clinical documentation for OSA indication

    When OSA‑related criteria are claimed, submit medical records (e.g., chart notes) documenting inability to tolerate positive airway pressure therapy or documentation of reduced sleep‑related impairment as specified.

    • For inability to tolerate PAP: submit chart notes documenting intolerance.
    • For continuing OSA benefit: submit records documenting reduction in sleep‑related impairment and status of PAP therapy (continuing therapy if applicable).
    Denial Risk

    Missing recent HbA1c — one‑time 2‑month grace for reauthorization

    If no HbA1c is provided for reauthorization, a one‑time 2‑month approval may be granted; subsequent requests without a recent HbA1c (within 6 months) will be denied.

    • At least one HbA1c must have been obtained in the previous 6 months for reauthorization.
    • If HbA1c is not provided, approve only for 2 months one time; deny after the first grace authorization if A1c remains missing.

    Definitions and Related Terms

    inv-15: SGLT2 inhibitor — definition / reference to SGLT2 inhibitor class
    Class definitionSodium-glucose cotransporter 2 (SGLT2) inhibitors are referenced as a diabetes therapy class used in step/alternative pathways
    Role in criteriaTrial and failure, contraindication, or intolerance to an SGLT2 inhibitor is a pathway requirement (2.1.2.1)
    Continuation optionApproval pathway allows continued SGLT2 inhibitor use with HbA1c > 7% as an alternative (2.1.2.2)
    inv-16: Chronic kidney disease criteria — UACR > 100 mg/g and eGFR 25-75 mL/min/1.73 m2
    UACR criterion> 100 mg/g
    eGFR criterion25-75 mL/min/1.73 m2
    UsageSpecified together as chronic kidney disease criteria within the ASCVD/CKD approval pathway

    Background

    Glucagon‑like peptide‑1 (GLP‑1) receptor agonists are indicated as glucose‑lowering agents for type 2 diabetes and are considered in this guideline for patients who may also have cardiovascular or renal disease. The coverage criteria specify clinical prerequisites for weekly GLP‑1 therapy, including documented diagnosis of Type 2 Diabetes, required prior trials (for example, metformin and a trial of liraglutide unless contraindicated), and comorbidity‑driven pathways such as ASCVD or chronic kidney disease with specified eGFR and UACR thresholds. Prior authorization is required for the listed products with a standard approval length of 12 months, and supporting documentation (including recent HbA1c values) is required for initial and ongoing coverage.

    Policy Summary
    Payercareoregon
    PolicyDiabetic GLP-1 Agonists (Weekly) — Prior Authorization Guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 21, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documenting required trials (including liraglutide) and a recent HbA1c within 6 months for reauthorization.
    SourceLink
    On This Page
    Coverage Criteria for Weekly GLP-1 AgonistsClinical Parameters and Coding-related CriteriaProvider Actions, Documentation & Prior AuthorizationDefinitions and Related TermsBackground